Biotech Values

[iwfal]

ZGEN -

The BS on this board asserting that BMY screwed ZGEN shareholders with respect to IFN Lambda should now immediately cease.

Hardly. I'll make you the following wager - that in 2017 lambda has bigger sales than the INHX drug (and if it is sold as a doublet its revenue is counted at 1/2 of the doublet sales). I don't think I have a huge advantage over the counter-position. But I don't think you do either, which is the point. And no different than the position I espoused 2 years ago. (At some point before 2017 I might change my mind based upon data - but in aggregate over the last year or two... dual DAAs aren't doing so well in G1a.)